AMLX

Amylyx Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth↓ 3/10
  • Momentum↑ 9/10
Amylyx Pharmaceuticals sales and earnings growth
AMLX Growth
Neutral
  • Revenue Y/Y↓ -100.34%
  • EPS Y/Y↑ 53.14%
  • FCF Y/Y↓ -61.66%
Amylyx Pharmaceuticals gross and profit margin trends
AMLX Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↑ 22448.40%
  • ROIC↓ -128.50%
Amylyx Pharmaceuticals net debt vs free cash flow
AMLX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Amylyx Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗